×

Cancer Vaccines And Methods Of Treatment Using The Same

  • US 20160030536A1
  • Filed: 03/14/2014
  • Published: 02/04/2016
  • Est. Priority Date: 03/15/2013
  • Status: Active Grant
First Claim
Patent Images

1. A vaccine comprising(a) a nucleic acid encoding one or more amino acid sequence(s) selected from the group consisting of:

  • (i) amino acid sequence of tyrosinase (Tyr) (SEQ ID NO;

    2);

    (ii) amino acid sequence of tyrosinase-related protein 1 (TYRP1) (SEQ ID NO;

    4);

    (iii) amino acid sequence of tyrosinase-related protein 2 (TYRP2) (SEQ ID NO;

    6);

    (iv) amino acid sequence of melanoma-associated antigen 4 protein (MAGEA4) (SEQ ID NO;

    8);

    (v) amino acid sequence of growth hormone release hormone (GHRH) (SEQ ID NO;

    10);

    (vi) amino acid sequence of MART-1/melan-A antigen (MART-1/Melan-A) (SEQ ID NO;

    12);

    (vii) amino acid sequence of cancer testis antigen (NY-ESO-1) (SEQ ID NO;

         14);

    (viii) amino acid sequence of cancer testis antigen II (NY-ESO-2)(SEQ ID NO;

    16);

    (ix) amino acid sequence of PRAME (SEQ ID NO;

    18)(x) amino acid sequence of WT1 (SEQ ID NO;

    20);

    (xi) amino acid sequence of WT1 (SEQ ID NO;

    22); and

    (xii) amino acid sequence of hTERT (SEQ ID NO;

    24);

    (b) a nucleic acid encoding one or more amino acid sequence(s) selected from the group consisting of;

    (i) amino acid sequence that is 95% identical or greater to the amino acid sequence of tyrosinase (Tyr) (SEQ ID NO;

    2);

    (ii) amino acid sequence that is 95% identical or greater to the amino acid sequence of tyrosinase-related protein 1 (TYRP1) (SEQ ID NO;

         4);

    (iii) amino acid sequence that is 95% identical or greater to the amino acid sequence of tyrosinase-related protein 2 (TYRP2) (SEQ ID NO;

         6);

    (iv) amino acid sequence that is 95% identical or greater to the amino acid sequence of melanoma-associated antigen 4 protein (MAGEA4) (SEQ ID NO;

         8);

    (v) amino acid sequence that is 95% identical or greater to the amino acid sequence of growth hormone release hormone (GHRH) (SEQ ID NO;

         10);

    (vi) amino acid sequence that is 95% identical or greater to the amino acid sequence of MART-1/melan-A antigen (MART-1/Melan-A)(SEQ ID NO;

         12);

    (vii) amino acid sequence that is 95% identical or greater to the amino acid sequence of cancer testis antigen (NY-ESO-1)(SEQ ID NO;

         14);

    (viii) amino acid sequence that is 95% identical or greater to the amino acid sequence of cancer testis antigen II (NY-ESO-2)(SEQ ID NO;

    16);

    (ix) amino acid sequence that is 95% identical or greater to the amino acid sequence of PRAME (SEQ ID NO;

         18);

    (x) amino acid sequence that is 95% identical or greater to the amino acid sequence of WT1 (SEQ ID NO;

    20);

    (xi) amino acid sequence that is 95% identical or greater to the amino acid sequence of WT1 (SEQ ID NO;

    22); and

    (xii) amino acid sequence that is 95% identical or greater to the amino acid sequence of hTERT (SEQ ID NO;

    24);

    or(c) combination of (a) and (b).

View all claims
  • 0 Assignments
Timeline View
Assignment View
    ×
    ×